Multimodality treatment warranted for ovarian cancer: Immunotherapy, a prerequisite to improve prognosis for this vicious disease

Immunotherapy

Volumn 1, Issue 2, 2009, Pages 163-165

  Leffers, Ninke ^a   Daemen, Toos ^a   Van Der Zee, Ate G J ^a   Nijman, Hans W ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; FAS LIGAND; HLA ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; VIRUS VACCINE;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CHEMOTHERAPY; CYTOKINE RELEASE; CYTOREDUCTIVE SURGERY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG TARGETING; EDITORIAL; GENE MUTATION; GENOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TH0 CELL; TREATMENT PLANNING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; CANCER VACCINES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS; TUMOR ESCAPE;

EID: 77953370987     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/1750743X.1.2.163     Document Type: Editorial

References (16)

1. Zhang L, Conejo-Garcia JR, Katsaros D et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 348(3), 203-213 (2003).
2. Curiel TJ, Coukos G, Zou L et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004).
3. Leffers N, Gooden MJ, de Jong RA et al.: Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. 58(3), 449-459 (2009).
4. +/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl Acad. Sci. USA 102(51), 18538-18543 (2005).
5. Sabbatini P, Odunsi K: Immunologic approaches to ovarian cancer treatment. J. Clin. Oncol. 25(20), 2884-2893 (2007).
6. Finn OJ: Cancer immunology. N. Engl. J. Med. 358(25), 2704-2715 (2008).
7. Garnett CT, Schlom J, Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clin. Cancer Res. 14(11), 3536-3544 (2008).
8. Laheru D, Lutz E, Burke J et al.: Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin. Cancer Res. 14(5), 1455-1463 (2008).
9. Conroy H, Marshall NA, Mills KH: TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene 27(2), 168-180 (2008).
10. Buckanovich RJ, Facciabene A, Kim S et al.: Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat. Med. 14(1), 28-36 (2008).
11. Croci DO, Zacarias Fluck MF, Rico MJ et al.: Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor micro-environment. Cancer Immunol. Immunother. 56(11), 1687-1700 (2007).
12. Begley J, Ribas A: Targeted therapies to improve tumor immunotherapy. Clin. Cancer Res. 14(14), 4385-4391 (2008).
13. Whiteside TL: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904-5912 (2008).
14. Yuan J, Gnjatic S, Li H et al.: CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit. Proc. Natl Acad. Sci. USA 105(51), 20410-20415 (2008).
15. Adair SJ, Hogan KT: Treatment of ovarian cancer cell lines with 5-aza-2′-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother. 58(4), 589-601 (2009)
16. Spannuth WA, Sood AK, Coleman RL: Angiogenesis as a strategic target for ovarian cancer therapy. Nat. Clin. Pract. Oncol. 5(4), 194-204 (2008).